Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PanCytoVir in Non-hospitalized COVID-19
NCT05442983Phase 2Completed
- Sponsor
- TrippBio
- Start
- Jul 2022
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of probenecid in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by TrippBio. Primary endpoint: Time to Viral Clearance at 5 days. Started Jul 2022; status: completed.
02
Drugs
probenecid
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05442983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442983.